ResearchResearch summary
Fecal fungal patterns and visceral sensitivity in IBS
A small IBS study found fecal fungal-community associations; experiments suggesting causality were conducted in rats, not people.
In this pathway
- Current topic
- Fecal fungal patterns and visceral sensitivity in IBSCurrent

Bottom line
In a small IBS-cohort comparison, fecal fungal-community patterns differed across healthy volunteers and two IBS sensitivity groups. This is a human association, not evidence that fungi caused symptoms. Experiments that manipulated fungi and reduced visceral hypersensitivity were conducted in rats, not people.
Why this source matters
This study gives a narrow example of an IBS-associated fecal mycobiome finding. It helps distinguish that human association from the proposed broad Candida syndrome and from SIFO, which is defined in a different population and by small-intestinal aspirate culture.
Study and population
The human participants were subgroups of the Maastricht IBS cohort, which included 540 patients with IBS and 205 healthy controls. The analysis summarized here included 18 healthy volunteers, 19 people with IBS and visceral hypersensitivity, and 20 with normal visceral sensitivity. IBS was diagnosed using Rome III criteria. The sensitivity groups were classified by rectal barostat testing; the hypersensitivity threshold was a visual-analogue pain score of at least 20 mm at 26 mmHg. Participants had not used antibiotics or antifungals during the three months before sampling. No person was treated as part of this human comparison.
What was tested
The investigators compared fecal fungal communities using ITS1 metabarcoding and assessed diversity and group signatures. In Long-Evans rats, fluconazole or nystatin was given for 21 days before water-avoidance stress, and visceral sensitivity was measured by colorectal distension. Other experiments transferred pooled caecal contents and tested soluble beta-glucan at 20 or 50 mg/kg and a SYK inhibitor at 1, 10, or 30 mg/kg. Ex-vivo tissue and mast-cell assays explored fungal immune signaling. These are preclinical experiments, separate from the observational human comparison.
Results
The combined share of Saccharomyces cerevisiae and Candida albicans was 57% of fungal sequencing reads among 18 healthy volunteers, 76% among 19 hypersensitive IBS participants, and 83% among 20 normosensitive IBS participants. The combined share did not differ between the IBS groups, but differed between each IBS group and controls. These percentages describe relative reads, not fungal counts or infection.
Shannon diversity was higher in controls than in hypersensitive IBS (P<.01) and normosensitive IBS (P<.001); the figure used 16–20 participants per group. A stability-selection signature distinguished hypersensitive IBS from controls with AUC>0.9 (P<.01), but was not tested in a separate validation cohort. Other comparisons were described as discriminating well, without exact AUCs in the main text.
In rats, fluconazole and nystatin each prevented water-avoidance-induced hypersensitivity. After combined fluconazole and nystatin reduced established sensitivity, caecal contents from untreated maternally separated donors restored it; contents from fungicide-treated donors and non-handled donors did not. The transfer groups had eight rats each. Soluble beta-glucan at 50 mg/kg reduced or prevented sensitivity while 20 mg/kg did not; 50 mg/kg twice daily for one week reversed established post-stress sensitivity. A SYK inhibitor also reversed sensitivity. These results do not estimate effects in people.
Applicability
The human findings apply to a selected group of people with IBS whose fecal fungal communities were compared by sensitivity status. They do not establish an infection, broad Candida overgrowth, or SIFO diagnosis. The animal results suggest mechanisms for further research but do not show that antifungals or other tested agents help people with IBS.
Limitations
The human sample was small, drawn from one cohort, and measured at one time. The authors said the association requires replication and does not establish a causal link. Sequencing measured relative community composition rather than organism counts. Some figure analyses included 16–20 people per group, and the paper does not explain the missing samples. The reported AUC was not externally validated as a diagnostic test.
The rat and human fungal communities overlapped only partly. Rat experiments and laboratory assays cannot establish human treatment benefit or safety. Rat outcomes were plotted as means with standard errors and significance markers, without tabulated absolute effect estimates or confidence intervals. Adverse events and rat tolerability were not reported. The study measured fecal fungal communities, not small-intestinal aspirate-defined SIFO, and it did not test the proposed broad multisystem Candida syndrome.
Contribution to the evidence
Contextual. The study documents a limited association between fecal mycobiome patterns and IBS sensitivity groups. It qualifies any claim that no human fungal-community association exists in IBS, while leaving the broad Candida claim unsupported: the human data are observational, the authors call for replication, and causal interventions were confined to rats.
Practical change
No practical change. This study does not show that Candida causes a person's symptoms, validate stool sequencing as a diagnostic test, or test a human treatment. It does not support a broad Candida diagnosis or antifungal treatment for IBS.
Funding and conflicts
Sara Botschuijver was supported by The Netherlands Digestive Diseases Foundation, project 1CDP005. Wouter de Jonge was supported by an NWO VIDI grant and Marie Curie ETN grant 641665. De Jonge reported consultancy fees and research grants from GlaxoSmithKline and grants from Dr Willmar Schwabe and Mead Johnson Nutrition Pediatric Institute. René van den Wijngaard reported a grant from Dr Willmar Schwabe; the other authors reported no competing financial interests. Guus Roeselers and Heleen H. de Weerd were affiliated with Danone-Nutricia Research at publication.
Source
Read the complete publisher-version PDF from Amsterdam UMC, Gastroenterology 2017;153(4):1026–1039 (online 15 June 2017; DOI: 10.1053/j.gastro.2017.06.004).
Study type, population, and sample scale
- Study type
- Cross-sectional human case-control comparison with parallel rat experiments and laboratory assays
- Population
- 18 healthy volunteers and 39 people with IBS from a Maastricht cohort, split into 19 with visceral hypersensitivity and 20 with normal visceral sensitivity
- Sample scale
- 57 human participants; rat groups had 7–9 animals depending on the experiment, with 8 recipients in each caecal-transfer group
Results
- In fecal fungal sequencing reads, Saccharomyces cerevisiae and Candida albicans together made up 57% for the 18 healthy volunteers, 76% for the 19 IBS participants with visceral hypersensitivity, and 83% for the 20 with normal sensitivity. The two IBS groups did not differ in this combined share; each differed from controls. These are relative read percentages, not organism counts, infection rates, or diagnoses.
- Shannon diversity was higher in healthy volunteers than in the hypersensitive IBS group (P<.01) and the normosensitive IBS group (P<.001). The figure reports 16–20 participants per group for this analysis; reasons for missing samples are not reported.
- A stability-selection signature distinguished hypersensitive IBS from healthy volunteers with an AUC greater than 0.9 (P<.01). The study did not validate a diagnostic classifier in a separate cohort, and it did not report exact AUCs for the other comparisons in the main text.
- In rats, 21 days of fluconazole or nystatin prevented water-avoidance-induced visceral hypersensitivity, and caecal material from untreated maternally separated donors restored it after fungicide treatment. Soluble beta-glucan at 50 mg/kg, but not 20 mg/kg, and a SYK inhibitor also reduced or reversed sensitivity. Prevention groups had 8–9 rats and transfer groups had 8 recipients each; no human treatment was tested.
Limitations
- The human analysis included 18 healthy volunteers and 39 IBS participants from one cohort and was cross-sectional.
- It cannot determine whether fungal patterns preceded, caused, or followed the IBS phenotype; the authors called for replication in another cohort.
- Sequencing results describe relative fungal reads, and the figure's diversity analyses used 16–20 participants per group.
- Relative reads are not absolute organism counts or disease measures, and the paper does not report reasons for outcome-specific missing samples.
- A stability-selection signature separated one pair of groups with AUC greater than 0.9.
- There was no separate-cohort validation, no established clinical cutoff, and no human diagnostic-utility study.
- Fungicide, transfer, beta-glucan, and SYK-pathway experiments were conducted in rats or laboratory systems.
- Rat results do not establish human causality, treatment benefit, dose, or safety; the human and rat fungal communities overlapped only partially.
- The article does not report adverse events, clinical safety outcomes, or rat tolerability outcomes.
- Safety cannot be inferred from the absence of reported harms.
Applies to
- What one small, selected IBS-cohort comparison found about relative fecal fungal-community patterns across sensitivity groups.
- Animal and laboratory hypotheses about how fungal signals might affect visceral sensitivity.
Does not apply to
- Diagnosing a Candida infection, broad Candida syndrome, or SIFO from symptoms or stool sequencing.
- Showing that fungal differences caused IBS symptoms in people or validating a human diagnostic test.
- Evidence that antifungals, beta-glucans, or a SYK inhibitor treat IBS in people.
Contribution to the current conclusion
Contextual
The human comparison documents a limited association between fecal fungal-community patterns and IBS sensitivity groups. It did not establish human causality or test a broad Candida syndrome; the causal manipulations were in rats, so the study does not support a treatment or diagnosis change.
Related evidence mapPractical change or no change
No practical change. The limited IBS association does not establish Candida as a cause of symptoms, and the causal experiments were in rats. The study does not support broad Candida diagnosis or human antifungal treatment.
Funding and conflicts
- Funding
- Sara Botschuijver was supported by The Netherlands Digestive Diseases Foundation, project 1CDP005; Wouter de Jonge was supported by an NWO VIDI grant and Marie Curie ETN grant 641665.
- Conflicts
- Wouter de Jonge reported consultancy fees and research grants from GlaxoSmithKline and research grants from Dr Willmar Schwabe and Mead Johnson Nutrition Pediatric Institute. René van den Wijngaard reported a research grant from Dr Willmar Schwabe; other authors reported no competing financial interests. Guus Roeselers and Heleen H. de Weerd were affiliated with Danone-Nutricia Research at publication.
- Paper date
- 2017-10-01
Sources
View all 1 source
- Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats
- Source type
- Observational study
- Published
- 2017-10-01